Skip to main content
Premium Trial:

Request an Annual Quote

Optimata, Blueprint, Rosetta, GeneGo, Genomatix


Optimata Validates Distributed Virtual Patient Technology

Optimata, a biosimulation startup based in Ramat Gan, Israel, said last week that it is in the process of validating a distributed version of its proprietary Virtual Patient Engine technology.

The company said it is currently using the platform in a clinical trial at Nottingham City Hospital in the UK and at the Soroka Medical Center in Israel to predict breast cancer therapy outcomes for several cancer drugs, including Adriamycin, Docetaxel, Paclitaxel, Vinorelbine, and Tamoxifen.

The Virtual Patient Engine uses proprietary algorithms to "mimic the physiological attributes of specific patients in order to evaluate the efficacy and safety of dosing and scheduling regimens for cancer drugs," Optimata said in a statement.

The new, distributed, system can accelerate this process by a factor of 10, Optimata said.

The distributed version, which will allow customers to run the software on their existing desktop infrastructure, " will make the Virtual Patient Engine more readily accessible to drug developers, hospitals, and other potential users," said Levon Arakelyan, the company's CTO, in a statement.

Company officials declined further comment, citing the ongoing clinical trial.

Blueprint to Provide Pre-Publication Curation for Journal of Biomolecular Screening

The Blueprint Initiative said last week that it has entered into an agreement with Sage Publications to add data from pre-publication manuscripts in Sage's Journal of Biomolecular Screening into BIND (Biomolecular Interaction Network Database).

Sage will incorporate BIND IDs into the manuscripts, Blueprint said.

SAGE joins several science publishers who have entered into curation relationships with Blueprint, including AAAS/Science, Nature Publishing Group, Cell Press, and Blackwell Publishing.

Rosetta and GeneGo to Integrate Software Products

Rosetta Biosoftware and GeneGo said last week that they have agreed to establish interoperability between Rosetta Biosoftware's Resolver gene expression analysis system and GeneGo's MetaCore pathway analysis platform.

Once the products are integrated, researchers will be able to exchange data between the MetaCore and Resolver systems in order to analyze gene expression data and perform sophisticated pathway analysis, the companies said.

Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware, said in a statement that customers of both products will be able to use the combined system to determine on- and off-target effects and to add biological context to gene expression data.

CNRG Takes Global License to Genomatix Pathway Software

Genomatix Software said last week that it has closed a contract with the French National Genomic Research Consortium (CNRG) that provides researchers from the French National Genopoles Network with access to the company's GenomatixSuitePE pathway-analysis platform.

Part of the contract provides for on-site training and scientific seminars at the various "Genopole" clusters across France.

Klaus May, head of sales and marketing at Genomatix, said in a statement that the CNRG agreement marks the company's third large-scale deal with a governmental institution. Previous agreements include the US National Institutes of Health and Finland's CSC (Finnish IT Center for Science).

"We further strive to coordinate individual academic subscriptions to a larger institution-wide or nation-wide level," May said.

Filed under

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.